Spectrum Can Generate Profits From Misfit Cancer Drugs HENDERSON, Nev. (TheStreet) -- Spectrum Pharmaceuticals recently announced the purchase of Talon Therapeutics and its drug Marqibo, a liposomal formulation of vincristine approved last year for the treatment of a rare type of leukemia. Marqibo's commercial potential is nowhere close to a cancer drug like Pharmacyclics' ibrutinib, but for Spectrum, the acquisition could still be quite profitable ...
July 25, 2013 - TheStreet.com